253 related articles for article (PubMed ID: 22835388)
1. Temporal trends in cause of death among Swedish and US men with prostate cancer.
Epstein MM; Edgren G; Rider JR; Mucci LA; Adami HO
J Natl Cancer Inst; 2012 Sep; 104(17):1335-42. PubMed ID: 22835388
[TBL] [Abstract][Full Text] [Related]
2. Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.
Feuer EJ; Merrill RM; Hankey BF
J Natl Cancer Inst; 1999 Jun; 91(12):1025-32. PubMed ID: 10379965
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.
Stattin P; Holmberg E; Johansson JE; Holmberg L; Adolfsson J; Hugosson J;
J Natl Cancer Inst; 2010 Jul; 102(13):950-8. PubMed ID: 20562373
[TBL] [Abstract][Full Text] [Related]
4. What do prostate cancer patients die of?
Riihimäki M; Thomsen H; Brandt A; Sundquist J; Hemminki K
Oncologist; 2011; 16(2):175-81. PubMed ID: 21257717
[TBL] [Abstract][Full Text] [Related]
5. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.
Hankey BF; Feuer EJ; Clegg LX; Hayes RB; Legler JM; Prorok PC; Ries LA; Merrill RM; Kaplan RS
J Natl Cancer Inst; 1999 Jun; 91(12):1017-24. PubMed ID: 10379964
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations.
Häggström C; Stocks T; Nagel G; Manjer J; Bjørge T; Hallmans G; Engeland A; Ulmer H; Lindkvist B; Selmer R; Concin H; Tretli S; Jonsson H; Stattin P
Epidemiology; 2014 Nov; 25(6):823-8. PubMed ID: 25207955
[TBL] [Abstract][Full Text] [Related]
7. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States.
Fang F; Keating NL; Mucci LA; Adami HO; Stampfer MJ; Valdimarsdóttir U; Fall K
J Natl Cancer Inst; 2010 Mar; 102(5):307-14. PubMed ID: 20124521
[TBL] [Abstract][Full Text] [Related]
8. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.
Collin SM; Martin RM; Metcalfe C; Gunnell D; Albertsen PC; Neal D; Hamdy F; Stephens P; Lane JA; Moore R; Donovan J
Lancet Oncol; 2008 May; 9(5):445-52. PubMed ID: 18424233
[TBL] [Abstract][Full Text] [Related]
9. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
[TBL] [Abstract][Full Text] [Related]
10. Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
Hoffman RM; Koyama T; Albertsen PC; Barry MJ; Daskivich TJ; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Potosky AL; Penson DF
J Gen Intern Med; 2015 Jul; 30(7):924-34. PubMed ID: 25678374
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database.
Stephenson RA
Urol Clin North Am; 2002 Feb; 29(1):173-81. PubMed ID: 12109343
[TBL] [Abstract][Full Text] [Related]
12. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
[TBL] [Abstract][Full Text] [Related]
14. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
15. Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013.
Castañeda-Avila MA; Ortiz-Ortiz KJ; Torres-Cintrón CR; Birmann BM; Epstein MM
Int J Cancer; 2020 Jan; 146(1):35-43. PubMed ID: 30802944
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Welch HG; Albertsen PC
J Natl Cancer Inst; 2009 Oct; 101(19):1325-9. PubMed ID: 19720969
[TBL] [Abstract][Full Text] [Related]
17. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
18. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.
Hugosson J; Carlsson S; Aus G; Bergdahl S; Khatami A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Lancet Oncol; 2010 Aug; 11(8):725-32. PubMed ID: 20598634
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
20. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program.
Smart CR
Cancer; 1997 Nov; 80(9):1835-44. PubMed ID: 9351557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
